ALK and non-small cell lung carcinoma: Clinical studies in non-small cell lung cancer have shown alectinib (an inhibitor of ALK and ALK-variant proteins resulting from rearrangement of the ALK locus) to be an effective therapy in tumors with ALK rearrangements.